Wide Ranks

LGND

Ligand Pharmaceuticals Incorpor

122.55

Top Statistics
Market Cap 2 B Forward PE 20.32 Revenue Growth 57.60 %
Current Ratio 12.49 Trailing PE 49.22 Earnings Growth 0.00 %
Profit Margins 29.68 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 39.97 Enterprise / Revenue 13.80 Price To Sales Trailing12 Months 15.19
Profitability
Profit Margins 29.68 % Operating Margins 21.14 %
Balance Sheet
Total Cash 219 M Total Cash Per Share 11.62 Total Debt 7 M
Total Debt To Equity 0.8750 Current Ratio 12.49 Book Value Per Share 44.84
All Measures
Short Ratio 631.00 % Message Board Id finmb_30820 Shares Short Prior Month 1 M
Return On Equity 0.0600 City Jupiter Uuid bc587d73-d759-3a5b-ad33-06c1e22b5803
Previous Close 124.33 First Trade Date Epoch Utc 722 M Book Value 44.84
Beta 0.8960 Total Debt 7 M Volume 88894
Price To Book 2.73 Last Split Date 1 B Fifty Two Week Low 57.00
Total Cash Per Share 11.62 Total Revenue 152 M Shares Short Previous Month Date 1 B
Target Median Price 140.00 Audit Risk 6 Max Age 86400
Recommendation Mean 1.57 Sand P52 Week Change 0.3133 Operating Margins 21.14 %
Last Dividend Value 9.36 Target Mean Price 140.25 Net Income To Common 45 M
Short Percent Of Float 0.0609 Implied Shares Outstanding 19 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 120270 Average Volume10days 120270
Total Cash 219 M Next Fiscal Year End 1 B Revenue Per Share 8.51
Held Percent Insiders 0.0189 Ebitda Margins 34.53 % Trailing PE 49.22
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 5
Regular Market Previous Close 124.33 Target Low Price 125.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 109.38 Open 123.65 Free Cashflow 16 M
State FL Dividend Yield 0.00 % Return On Assets 0.0130
Time Zone Short Name EST Board Risk 4 Trailing Eps 2.49
Day Low 121.06 Address1 555 Heritage Drive Shares Outstanding 18 M
Compensation Risk 4 Price Hint 2 Target High Price 157.00
Website https://www.ligand.com 52 Week Change 1.10 Average Volume 109723
Forward Eps 5.98 Recommendation Key buy Quick Ratio 1083.40 %
Last Split Factor 1603:1000 Regular Market Day High 124.58 Is_sp_500 False
Profit Margins 29.68 % Debt To Equity 0.8750 Fifty Two Week High 129.90
Day High 124.58 Shares Short 831448 Regular Market Open 123.65
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 13.80
Revenue Growth 57.60 % Shares Percent Shares Out 0.0440 Operating Cashflow 76 M
Currency USD Time Zone Full Name America/New_York Market Cap 2 B
Is_nasdaq_100 False Zip 33458 Quote Type EQUITY
Industry Biotechnology Ex Dividend Date 1 B Overall Risk 4
Regular Market Day Low 121.06 Held Percent Institutions 1.00 Long Name Ligand Pharmaceuticals Incorporated
Address2 Suite 200 Enterprise To Ebitda 39.97 Current Price 122.55
Financial Currency USD Current Ratio 12.49 Gross Margins 78.77 %
Industry Disp Biotechnology Number Of Analyst Opinions 8 Country United States
Float Shares 18 M Two Hundred Day Average 92.09 Governance Epoch Date 1 B
Ir Website http://investor.ligand.com/Investors/Investor-Overview/default.aspx Price To Sales Trailing12 Months 15.19 Enterprise Value 2 B
Forward PE 20.32 Regular Market Volume 88894 Last Dividend Date 1 B
Ebitda 52 M Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.

Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.

The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.

In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications.

The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.

Further, it sells Captisol materials.

Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.